Caring for patients with kidney disease: Shifting the paradigm from evidence-based medicine to patient-centered care

Nephrology Dialysis Transplantation

Volumn 31, Issue 3, 2016, Pages 368-375

  O'Hare, Ann M ^a,b   Rodriguez, Rudolph A ^a,b   Bowling, Christopher Barrett ^c,d  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

evidence based medicine; kidney disease; older adults; paradigm; patient centered care

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL;

CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DISEASE COURSE; END STAGE RENAL DISEASE; EVIDENCE BASED MEDICINE; GLOMERULUS FILTRATION RATE; HEALTH CARE QUALITY; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LIFE EXPECTANCY; MOLECULAR EVOLUTION; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; DISEASE MANAGEMENT; PROCEDURES; RENAL INSUFFICIENCY, CHRONIC;

DISEASE MANAGEMENT; EVIDENCE-BASED MEDICINE; HUMANS; PATIENT-CENTERED CARE; RENAL INSUFFICIENCY, CHRONIC;

EID: 84960075057     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv003     Document Type: Review

References (89)

1. Evidence-Based Medicine Working Group. Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA 1992; 268: 2420-2425
2. Krumholz HM. The new cholesterol and blood pressure guidelines: perspective on the path forward. JAMA 2014; 311: 1403-1405
3. Upshur RE, Tracy CS. Is evidence-based medicine overrated in family medicine? Yes. Can Fam Physician 2013; 59: 1160-1161
4. Sackett DL. Clinical epidemiology. Am J Epidemiol 1969; 89: 125-128
5. Abrahamson J. Overdo$ed America: The Broken Promise of American Medicine. New York: Harper Collins, 2005
6. Moynihan R, Cassels A. Selling Sickness: how theworld's biggest pharmaceutical companies are turning us all into patients.New York: Nation Books, 2005
7. Upshur RE. Looking for rules in a world of exceptions: reflections on evidence-based practice. Perspect Biol Med 2005; 48: 477-489
8. Upshur R, Buetow S, Loughlin M, et al. Can academic and clinical journals be in financial conflict of interest situations? The case of evidence-based incorporated. J Eval Clin Pract 2006; 12: 405-409
9. Ioannidis JP, Greenland S, Hlatky MA, et al. Increasing value and reducing waste in research design, conduct, and analysis. Lancet 2014; 383: 166-175
10. Kushner HI. Evidence-based medicine and the physician-patient dyad. Perm J 2010; 14: 64-69
11. Stamatakis E, Weiler R, Ioannidis JP. Undue industry influences that distort healthcare research, strategy, expenditure and practice: a review. Eur J Clin Invest 2013; 43: 469-475
12. Upshur RE. Do clinical guidelines still make sense? No. Ann Family Med 2014; 12: 202-203
13. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-266
14. Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int 2014; 85: 49-61
15. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011; 80: 17-28
16. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013: 1-150
17. Levey AS, Stevens LA, Coresh J. Conceptual model of CKD: applications and implications. Am J Kidney Dis 2009; 53: S4-16
18. Hallan SI, Matsushita K, Sang Y, et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA 2012; 308: 2349-2360
19. Keirns CC, Goold SD. Patient-centered care and preference-sensitive decision making. JAMA 2009; 302: 1805-1806
20. Tinetti ME, Bogardus ST, Jr, Agostini JV. Potential pitfalls of diseasespecific guidelines for patients with multiple conditions. N Engl J Med 2004; 351: 2870-2874
21. Boyd CM, Kent DM. Evidence-based medicine and the hard problem of multimorbidity. J Gen Intern Med 2014; 29: 552-553
22. Reuben DB, Tinetti ME. Goal-oriented patient care-an alternative health outcomes paradigm. N Engl J Med 2012; 366: 777-779
23. Hoffmann TC, Montori VM, DelMar C. The connection between evidencebased medicine and shared decision making. JAMA 2014; 312: 1295-1296
24. Weiss CO, Boyd CM, YuQet al. Patterns of prevalent major chronic disease among older adults in the United States. JAMA 2007; 298: 1160-1162
25. Tinetti ME, Fried TR, Boyd CM. Designing health care for the most common chronic condition-multimorbidity. JAMA 2012; 307: 2493-2494
26. Upshur RE, Tracy S. Chronicity and complexity: is what's good for the diseases always good for the patients? Can FamPhysician 2008; 54: 1655-1658
27. Zulman DM, Asch SM, Martins SB, et al. Quality of care for patients with multiple chronic conditions: the role of comorbidity interrelatedness. J Gen Intern Med 2014; 29: 529-537
28. Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005; 294: 716-724
29. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047
30. O'Hare AM, Kaufman JS, Covinsky KE, et al. Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults? Ann Intern Med 2009; 150: 717-724
31. Zulman DM, Sussman JB, Chen X, et al. Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med 2011; 26: 783-790
32. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 2002; 162: 1682-1688
33. Van Spall HG, Toren A, Kiss A, et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 2007; 297: 1233-1240
34. Gurwitz JH, Goldberg RJ. Age-based exclusions from cardiovascular clinical trials: implications for elderly individuals (and for all of us): comment on the persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med 2011; 171: 557-558
35. Wenger NK. Exclusion of the elderly and women from coronary trials. Is their quality of care compromised? JAMA 1992; 268: 1460-1461
36. Gurwitz JH, Col NF, Avorn J. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. JAMA 1992; 268: 1417-1422
37. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-551
38. O'Hare AM, Hotchkiss JR, Kurella Tamura M, et al. Interpreting treatment effects from clinical trials in the context of real-world risk information: endstage renal disease prevention in older adults. JAMA Intern Med 2014; 174: 391-397
39. Whaley-Connell AT, Sowers JR, Stevens LA, et al. CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis 2008; 51: S13-S20
40. O'Hare AM, Hailpern SM, Pavkov ME, et al. Prognostic implications of the urinary albumin to creatinine ratio in veterans of different ages with diabetes. Arch Intern Med 2010; 170: 930-936
41. Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165: 936-946
42. Levey AS, Uhlig K. Which antihypertensive agents in chronic kidney disease? Ann Intern Med 2006; 144: 213-215
43. Tinetti ME, Fried T. The end of the disease era. Am J Med 2004; 116: 179-185
44. Bowling CB, Sharma P, Muntner P. Prevalence, trends and functional impairment associated with reduced estimated glomerular filtration rate and albuminuria among the oldest-old U.S. adults. Am J Med Sci 2014; 348: 115-120
45. Bowling CB, Booth JN, III, SaffordMMet al. Nondisease-specific problems and all-cause mortality in the REasons for Geographic and Racial Differences in Stroke study. J Am Geriatr Soc 2013; 61: 739-746
46. Schell JO, O'Hare AM. Illness trajectories and their relevance to the care of adults with kidney disease. Curr Opin Nephrol Hypertens 2013; 22: 316-324
47. O'Hare AM, Batten A, Burrows NR, et al. Trajectories of kidney function decline in the 2 years before initiation of long-term dialysis. Am J Kidney Dis 2012; 59: 513-522
48. Cooper BA, Branley P, Bulfone L, et al. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med 2010; 363: 609-619
49. Fink HA, Ishani A, Taylor BC, et al. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med 2012; 156: 570-581
50. Hemmelgarn BR, James MT, Manns BJ, et al. Rates of treated and untreated kidney failure in older vs younger adults. JAMA 2012; 307: 2507-2515
51. Li L, Astor BC, Lewis J, et al. Longitudinal progression trajectory of GFR among patients with CKD. Am J Kidney Dis 2012; 59: 504-512
52. Rosansky SJ, Glassock RJ. Is a decline in estimated GFR an appropriate surrogate end point for renoprotection drug trials? Kidney Int 2014; 85: 723-727
53. Mann JF, Schmieder RE, McQueenMet al Renal outcomes with telmisartan, ramipril, orboth, inpeopleathighvascularrisk(theONTARGETstudy): amulticentre, randomised, double-blind, controlled trial.Lancet 2008; 372: 547-553
54. Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659-663
55. O'Hare AM, Choi AI, Bertenthal D, et al. Age affects outcomes in chronic kidney disease. J Am Soc Nephro 2007; 18: 2758-2765
56. Jha AK, Zaslavsky AM. Quality reporting that addresses disparities in health care. JAMA 2014; 312: 225-226
57. Clase CM, Garg AX, Kiberd BA. Classifying kidney problems: can we avoid framing risks as diseases? BMJ 2004; 329: 912-915
58. American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. Guiding principles for the care of older adults withmultimorbidity: an approach for clinicians. J Am Geriatr Soc 2012; 60: E1-E25
59. Timbie JW, Hayward RA, Vijan S. Variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus. Arch Intern Med 2010; 170: 1037-1044
60. Gill TM. The central role of prognosis in clinical decision making. JAMA 2012; 307: 199-200
61. Reuben DB. Medical care for the final years of life: When you're 83, it's not going to be 20 years. JAMA 2009; 302: 2686-2694
62. Smith AK, White DB, Arnold RM. Uncertainty-the other side of prognosis. N Engl J Med 2013; 368: 2448-2450
63. Lee SJ, Leipzig RM, Walter LC. Incorporating lag time to benefit into prevention decisions for older adults. JAMA 2013; 310: 2609-2610
64. Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001; 285: 2750-2756
65. Barry MJ, Edgman-Levitan S. Shared decision making-pinnacle of patient-centered care. N Engl J Med 2012; 366: 780-781
66. Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academy Press, 2001
67. Upshur RE. The complex, the exhausted and the personal: reflections on the relationship between evidence-based medicine and casuistry. Commentary on Tonelli (2006), Integrating evidence into clinical practice: an alternative to evidence-based approaches. Journal of Evaluation in Clinical Practice 12, 248-256. J Eval Clin Pract 2006; 12: 281-288
68. Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA 2007; 298: 1209-1212
69. Kent DM, Lindenauer PK. Aggregating and disaggregating patients in clinical trials and their subgroup analyses. Ann Intern Med 2010; 153: 51-52
70. Tinetti ME, Studenski SA. Comparative effectiveness research and patients with multiple chronic conditions. N Engl J Med 2011; 364: 2478-2481
71. Odden MC, Peralta CA, Haan MN, et al. Rethinking the association of high blood pressure with mortality in elderly adults: the impact of frailty. Arch Intern Med 2012; 172: 1162-1168
72. Fried TR, McGraw S, Agostini JV, et al. Views of older persons with multiple morbidities on competing outcomes and clinical decision-making. J Am Geriatr Soc 2008; 56: 1839-1844
73. Bowling CB, Muntner P, Sawyer P, et al. Community mobility among older adults with reduced kidney function: a study of life-space. Am J Kidney Dis 2014; 63: 429-436
74. Kent DM, Alsheikh-Ali A, Hayward RA. Competing risk and heterogeneity of treatment effect in clinical trials. Trials 2008; 9: 30
75. Kent DM, Rothwell PM, Ioannidis JP, et al. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials 2010; 11: 85
76. Frank L, Basch E, Selby JV. The PCORI perspective on patient-centered outcomes research. JAMA 2014; 312: 1513-1514
77. Fleurence RL, Beal AC, Sheridan SE, et al. Patient-powered research networks aim to improve patient care and health research. Health Aff (Millwood) 2014; 33: 1212-1219
78. Ware JH, Hamel MB. Pragmatic trials-guides to better patient care? N Engl J Med 2011; 364: 1685-1687
79. Maciejewski ML, Bayliss EA. Approaches to comparative effectiveness research in multimorbid populations. Med care 2014; 52: S23-S30
80. Montori VM, Brito JP, Murad MH. The optimal practice of evidence-based medicine: incorporating patient preferences in practice guidelines. JAMA 2013; 310: 2503-2504
81. van Der Weijden T, Pieterse AH, Koelewijn-van Loon MS, et al. How can clinical practice guidelines be adapted to facilitate shared decision making? A qualitative key-informant study. BMJ Qual Saf 2013; 22: 855-863
82. Working Group on Health Outcomes for Older Persons with Multiple Chronic Conditions. Universal health outcome measures for older persons with multiple chronic conditions. J Am Geriatr Soc 2012; 60: 2333-2341
83. Fishman PA, Johnson EA, Coleman K, et al. Impact on seniors of the patient-centered medical home: evidence from a pilot study. Gerontologist 2012; 52: 703-711
84. Larson EB, Reid R. The patient-centered medical home movement: why now? JAMA 2010; 303: 1644-1645
85. Nelson KM, Helfrich C, Sun H, et al. Implementation of the patient-centered medical home in the Veterans Health Administration: associations with patient satisfaction, quality of care, staff burnout, and hospital and emergency department use. JAMA Intern Med 2014; 174: 1350-1358
86. Reid RJ, Coleman K, Johnson EA, et al. The Group Health medical home at year two: cost savings, higher patient satisfaction, and less burnout for providers. Health Aff (Millwood) 2010; 29: 835-843
87. Faber M, Voerman G, Erler A, et al. Survey of 5 European countries suggests that more elements of patient-centered medical homes could improve primary care. Health Aff (Millwood) 2013; 32: 797-806
88. Weisberg LS. The patient-centered medical home and the nephrologist. Adv Chronic Kidney Dis 2011; 18: 450-455
89. DuBose TD, Jr, Behrens MT, Berns A, et al. The patient-centered medical home and nephrology. J Am Soc Nephrol 2009; 20: 681-682